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The P2X7 receptor is a trimeric ATP-gated cation channel important in health and disease. 
We have observed that the specific phospholipase D (PLD)1 antagonist, CAY10593 impairs 
P2X7-induced shedding of the ‘low affinity’ IgE receptor, CD23. The current study 
investigated the mode of action of this compound on P2X7 activation. Measurements of 
ATP-induced ethidium+ uptake revealed that CAY10593 impaired P2X7-induced pore 
formation in human RPMI 8226 B cells, P2X7-transfected HEK-293 cells and peripheral 
blood mononuclear cells. Concentration response curves demonstrated that CAY10593 
impaired P2X7-induced pore formation in RPMI 8226 cells more potently than the PLD2 
antagonist CAY10594 and the non-specific PLD antagonist halopemide. Electrophysiology 
measurements demonstrated that CAY10593 also inhibited P2X7-induced inward currents. 
Notably, RT-PCR demonstrated that PLD1 was absent in RPMI 8226 cells, while choline-Cl 
medium or 1-butanol, which block PLD stimulation and signalling respectively did not 
impair P2X7 activation in these cells. This data indicates that CAY10593 impairs human 
P2X7 independently of PLD1 stimulation and highlights the importance of ensuring that 
compounds used in signalling studies downstream of P2X7 activation do not affect the 










P2X7 is a trimeric ligand-gated cation (Ca2+, Na+ and K+) channel present on various cell 
types and plays important roles in many disease states, including inflammatory, immune, 
neoplastic, musculoskeletal and neurological disorders [1]. Prolonged exposure of P2X7 to 
extracellular ATP opens a second permeability state or pore that allows the uptake of organic 
cations including fluorescent dyes such as ethidium+ [2]. Whether this second permeability 
state is attributed to intrinsic channel dilation [3], the pannexin-1 channel [4] or an alternate 
but unknown uptake pathway [5-7] remains controversial. Moreover, our understanding of 
this permeability state is further complicated with some [8-10] but not other [11-13] studies 
showing that P2X7-induced dye uptake involves the p38 mitogen-activated protein kinase. 
Regardless of the true identity of the P2X7 pore and the mechanism by which it opens, P2X7 
activation stimulates several intracellular signalling pathways to induce various cellular 
events including inflammatory mediator release, reactive oxygen and nitrogen species 
formation, and cell proliferation or death [14-15]. P2X7 activation also induces the shedding 
of cell-surface molecules including the ‘low-affinity’ IgE receptor, CD23 [16-19]. However, 
the intracellular signalling pathways that mediate this process are unknown.  
 
Phospolipase D (PLD) catalyses the hydrolysis of phosphatidylcholine to phosphatidic acid 
and choline, which subsequently participate in various cellular events [20]. Two isoforms of 
mammalian PLD have been described, PLD1 and PLD2 [20]. P2X7 activation can stimulate 
PLD in B cells [21-22] and macrophages [23-24]. P2X7-induced PLD stimulation in 
macrophages plays a role in the killing of intracellular mycobacteria [25-26] and the 
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generation of microvesicles capable of further macrophage activation [27]. In contrast, the 
role of P2X7-induced PLD stimulation in B cells remains unknown. 
 
We have previously shown that human RPMI 8226 B cells express P2X7, and that activation 
of P2X7 on these cells induces pore formation and the shedding of CD23 [17,28-29] During 
our preliminary investigations of the possible intracellular signalling enzymes involved in 
P2X7-induced CD23 shedding from RPMI 8226 cells we observed that the 1-(piperidin-4-
yl)-1H-benzo[d]imidazol-2(3H)-one analogue and specific PLD1 inhibitor, CAY10593 [30], 
significantly impaired P2X7-induced CD23 shedding. Therefore, the aim of this study was to 
investigate the mode of action by which CAY10593 impairs P2X7-induced CD23 shedding. 
Measurements of P2X7-induced pore formation and channel activity, and PLD analysis by 
RT-PCR demonstrated that CAY10593 impairs human P2X7 independently of PLD1. 
 




RPMI-1640 medium (containing 10 mM HEPES), ATP, poly-D-lysine, imipramine and 
diphenyleneiodonium were from Sigma Chemical Company (St. Louis, MO). Foetal bovine 
serum was from Bovogen Biologicals (East Keilor, Australia) or Lonza (Basal, Switzerland). 
DMEM:F12 medium (containing 10 mM HEPES), GlutaMAX, L-glutamine, 
penicillin/streptomycin and G418 were from Invitrogen (Grand Island, NY). Ficoll PaqueTM 
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PLUS was from GE Healthcare Bio-Sciences AB (Uppsala, Sweden). Dimethyl sulphoxide 
(DMSO) and ethidium bromide were from Amresco (Solon, OH). AZ10606120, 
AZ11645373, A-438079 and SB216763 were from Tocris Bioscience (Ellisville, MO). 
Rottlerin, LY294002, SB202190, SB203580, U0126 and SP600125 were from Merck 
Chemicals (Darmstadt, Germany). AG-126, GF109203X, D609, Fasudil, Y-27632 and 
AACOCF3 were from Enzo Life Sciences (Bristol, UK). CAY10593, CAY10594 and 
halopemide were from the Cayman Chemical Company (Ann Arbor, MI). Phycoerythrin (PE) 
or allophycocyanin (APC)-conjugated murine anti-human CD23 (clone EBVCS2), isotype 
control (clone P3.6.2.8.1), and APC-conjugated murine anti-human CD19 (clone HIB19) 
monoclonal antibodies (mAb) were from eBioscience (San Diego, CA). Primers were from 




Human RPMI 8226 multiple myeloma B cells and human A431 skin epithelial carcinoma 
cells (European Collection of Cell Cultures, Porton Down, UK) were maintained in complete 
RPMI-1640 medium (RPMI-1640 medium containing 10% foetal bovine serum and 2 mM 
GlutaMAX) at 37ºC and 95% air/5% CO2. HEK-293 cells (American Type Culture 
Collection, Rockville, MD) were maintained in complete DMEM:F12 medium (DMEM:F12 
medium containing 10% foetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin 
and 2 mM L-glutamine). A stable HEK-293 cell line expressing human P2X7 was established 
by clonal dilution and kept under G418 selection medium. Experiments with human blood 
were approved by the University of Wollongong Human Ethics Committee. Peripheral blood 
was collected into VACUETTE® lithium heparin tubes (Greiner Bio-One, Frickenhausen, 
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Germany) and diluted with an equal volume of phosphate-buffered saline. Peripheral blood 
mononuclear cells (PBMCs) were separated by density gradient centrifugation over Ficoll-
PaqueTM PLUS (560 x g for 20 min) and washed once in phosphate-buffered saline (450 x g 
for 10 min). 
 
Measurement of P2X7-induced pore formation by flow cytometry  
 
P2X7-induced pore formation in RPMI 8226 cells or PBMCs was assessed by flow 
cytometric measurements of ATP-induced ethidium+ uptake as described [17]. Briefly, cells 
suspended in NaCl medium (145 mM NaCl, 5 mM KCl, 5 mM glucose, 10 mM HEPES, pH 
7.4) (1 x 106 cells/ml) were pre-incubated in the absence or presence of antagonist (as 
indicated), and then with 25 µM ethidium+ in the absence or presence of ATP (as indicated) 
for 5 min at 37°C. In some experiments cells were suspended in choline-Cl medium (150 mM 
choline-Cl, 5 mM KCl, 5 mM glucose, 10 mM HEPES, pH 7.4). Incubations were stopped by 
addition of an equal volume of ice-cold MgCl2 medium (NaCl medium containing 20 mM 
MgCl2) and centrifugation (300 x g for 5 min). Cells were washed once with NaCl medium. 
PBMCs were also incubated with APC-conjugated anti-human CD19 mAb and washed once 
with NaCl medium. The mean fluorescence intensity (MFI) of ethidium+ uptake was 
determined using a LSR II flow cytometer (BD, San Jose, CA) (using a 575/26 nm band-pass 
filter) and FlowJo software (Tree Star, Ashland, OR). For PBMCs, lymphocytes and 
monocytes were gated by forward and side scatter and CD19 expression was detected using a 




Measurement of P2X7-induced CD23 shedding by flow cytometry 
 
P2X7-induced CD23 shedding from RPMI 8226 cells was indirectly assessed by flow 
cytometric measurements of ATP-induced loss of cell-surface CD23 as described [17]. 
Briefly, cells suspended in NaCl medium (1 x 106 cells/ml) were pre-incubated in the absence 
or presence of antagonist (as indicated), and then in the absence or presence of 1 mM ATP 
for 7 min at 37ºC. In some experiments, cells were suspended in either choline-Cl medium, 
KCl medium (150 mM KCl, 5 mM glucose, 10 mM HEPES, pH 7.4), or NaCl medium 
containing either 0.1 mM EGTA or 50 µM BAPTA-AM for 5 min, and then in the absence or 
presence of 1 mM ATP for 7 min at 37ºC. All ATP incubations were stopped by addition of 
an equal volume of ice-cold MgCl2 medium and centrifugation (300 x g for 5 min). Cells 
were washed once with NaCl medium and incubated with PE or APC-conjugated anti-human 
CD23 or isotype control mAb. The MFI of cell-surface CD23 expression was determined 
using flow cytometry (using a 575/26 or 660/20 nm band-pass filter for PE or APC 
respectively) and FlowJo software.  
 
Detection of PLD mRNA expression by RT-PCR 
 
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. Primer pairs (forward and reverse, respectively) 
to PLD1 were: 5’-TCATGTGTCATCCACCGTCT-3’ and 5’-
GGCGTGGAGTACCTGTCAAT-3’, and PLD2 [30] were: 5’-
GGCGATGAGATTGTGGACA-3’ and 5’-CTGGAAGAAGTCATCACAGA-3’. PCR 
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amplification was performed using the MyTaq One-Step RT-PCR Kit (Bioline, Sydney, 
Australia) according to the manufacturer’s instructions. PCR cycling conditions were 45°C 
for 20 min, 94°C for 2 min, 30 cycles of 94°C for 30 s, 54°C (PLD1 primer pair) or 57°C 
(PLD2 primer pair), and 72°C for 1 min, and a final step of 72°C for 5 min. Products were 
separated on a 2% agarose gel and visualised using ethidium bromide staining. 
 
Measurement of P2X7 channel activity by electrophysiology 
 
P2X7 channel activity in P2X7-transfected HEK-293 cells was assessed by 
electrophysiological measurements of ATP-induced currents as described [31]. Briefly, 
whole-cell patch-clamp recordings were performed at room temperature using an EPC10 
amplifier and Patchmaster acquisition software (HEKA, Lambrecht, Germany). ATP and 
CAY10593 were delivered using the RSC-160 fast-flow system (Bio-Logic Science 
Instruments, Claix, France). Membrane potential was clamped at –60 mV in all experiments. 
External solution was 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 13 mM D-
glucose, 10 mM HEPES, and internal solution was 145 mM NaCl, 10 mM HEPES, 10 mM 
EGTA. Both solutions were adjusted to pH 7.3 with 5 M NaOH and were 300-310 mOsm/L. 
 
Measurement of P2X7-induced pore formation using a fluorescent plate reader 
 
Ethidium+ uptake assays on human P2X7-transfected HEK-293 cells were performed using 
an Optima FLUOSTAR fluorescent plate reader (BMG Labtech,, Ortenberg, Germany). Cells 
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(5 x 104 cells/well) were incubated overnight in a 96-well poly-D-lysine coated plate. 
Ethidium+ (25 µM) was added in low divalent solution (145 mM NaCl, 5 mM KCl, 0.2 mM 
CaCl2, 13 mM glucose, 10 mM HEPES, pH 7.3). Cells were pre-incubated with CAY10593 
for 15 minutes at 37°C before measurements started. ATP was injected after 40 s 
measurements commenced. Fluorescence was measured using a 485 nm excitation filter and 
a 520 nm emission filter block. Gain was set at the beginning of the experiment to 30% 
required value and fluorescence measurements were taken every 10 s. 
 
Presentation of data and statistics 
 
Data is presented as mean ± SD. Differences between treatments were compared using the 
unpaired Student’s t-test using Prism 5 (Windows version 5.01; GraphPad Software, San 
Diego, CA) with P < 0.05 considered significant. Concentration response curves of 
log(agonist) vs. response, or log(inhibitor) vs. response were fitted using the least squares 




P2X7 antagonists inhibit ATP-induced pore formation in a concentration-dependent manner 
 
Specific P2X7 antagonists including AZ10606120 [32], AZ11645373 [33] and A-438079 
[34] have been characterised using cells expressing recombinant P2X7, however these 
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antagonists have been far less studied on cells expressing endogenous (or native) P2X7. 
RPMI 8226 cells have been previously shown to express endogenous P2X7 [17,28-29]. 
Therefore to test these specific P2X7 antagonists on endogenously expressed P2X7, RPMI 
8226 cells were pre-incubated in the absence or presence of increasing concentrations of 
AZ10606120, AZ11645373 or A-438079, and the ATP-induced ethidium+ uptake (pore 
formation) was measured by flow cytometry. AZ10606120, AZ11645373 and A-438079 
inhibited 1 mM ATP-induced ethidium+ uptake in a concentration-dependent manner, with 
maximal inhibition occurring at 100 nM, 300 nM and 10 µM and with an IC50 of 11 ± 1 nM,  
27 ± 3 nM and 900 ± 100 nM, respectively (Fig. 1).  
 
Changes in intracellular cation concentrations are not essential for P2X7-induced CD23 
shedding 
 
To assess a potential role for changes in intracellular cation concentrations in P2X7-induced 
CD23 shedding, ATP-induced CD23 shedding from RPMI 8226 cells was compared between 
cells suspended in NaCl medium (control) to cells suspended in either choline-Cl medium, 
KCl medium, or in NaCl medium containing EGTA or BAPTA-AM, which prevent Na+ 
influx, K+ efflux, Ca2+ influx or intracellular Ca2+ increases, respectively. ATP-induced CD23 
shedding was indirectly assessed by measuring the loss of cell-surface CD23 using an anti-
CD23 mAb and flow cytometry following 7 min incubation with 1 mM ATP, which is 
approximate to the t1/2 for this process [17,29]. As previously observed [17,29], ATP induced 
CD23 shedding from RPMI 8226 cells in NaCl medium (Fig. 2). ATP-induced CD23 
shedding was potentiated from cells suspended in either choline-Cl or KCl medium compared 
to cells in NaCl medium (Fig. 2A, B). In contrast, ATP-induced CD23 shedding was similar 
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from cells suspended in NaCl medium containing 100 µM EGTA or 50 µM BAPTA-AM 
compared to cells in NaCl medium (Fig. 2C, D). 
 
PLD antagonists inhibit P2X7-induced CD23 shedding  
 
To determine the involvement of intracellular signalling pathways in P2X7-induced CD23 
shedding, cells were pre-incubated in the presence of various enzyme antagonists (as listed in 
the Materials and Methods) or their corresponding diluent control, and the ATP-induced 
CD23 shedding assessed as above. Antagonist concentrations were based on previously used 
concentrations, and AZ10606120 was included as a positive control. As expected, 100 nM 
AZ10606120 significantly inhibited ATP-induced shedding of CD23 by 88 ± 9% (n=3). In 
contrast, most of the enzyme antagonists failed to significantly impair ATP-induced CD23 
shedding (results not shown). Of note, the PLD1 antagonist CAY10593 and to a lesser extent 
the PLD2 antagonist CAY10594 (both at 10 µM) significantly impaired ATP-induced CD23 
shedding (Fig. 3A). The non-selective PLD antagonist and structural analogue of CAY10593, 
halopemide (10 µM) however had no significant effect on ATP-induced CD23 shedding (Fig. 
3A). In the absence of ATP, no antagonist significantly altered cell-surface expression of 







PLD antagonists inhibit ATP-induced ethidium+ uptake in a concentration-dependent manner 
 
The above data indicates that the PLD1 antagonist, CAY10593, can inhibit P2X7-induced 
CD23 shedding. Therefore, the current study investigated the mode of action by which this 
compound impaired P2X7-induced CD23 shedding. The PLD2 antagonist CAY10594 and 
the non-selective PLD antagonist halopemide were studied as a comparison. To investigate 
whether CAY10593 impaired ATP-induced CD23 shedding by blocking P2X7 activation, 
RPMI 8226 cells were pre-incubated in the presence of DMSO (diluent control), CAY10593, 
CAY10594 or halopemide (each at 10 µM), and the ATP-induced ethidium+ uptake was 
measured. The PLD antagonists significantly inhibited ATP-induced ethidium+ uptake by 56 
± 4%, 20 ± 6% and 15 ± 5% respectively compared to ATP-induced ethidium+ uptake in cells 
pre-incubated with DMSO (Fig. 3B). In the absence of ATP, these antagonists did not 
significantly alter ethidium+ uptake compared to DMSO-treated cells (results not shown).  
 
The above data suggests that the inhibitory action of CAY10593 and CAY10594 on P2X7-
induced CD23 shedding is due to impaired P2X7 activation. Therefore to further characterise 
the effect of the above three PLD antagonists on P2X7 activation, cells were pre-incubated in 
the presence of increasing concentrations of each antagonist and the ATP-induced ethidium+ 
uptake measured, using 120 µM ATP which is approximate to the EC50 for ATP in this 
process [17,28]. CAY10593 inhibited ATP-induced ethidium+ uptake in a concentration-
dependent manner, with maximal inhibition occurring near 10 µM and an IC50 of 2.0 ± 0.5 
µM (Fig. 4). Inhibition of ATP-induced ethidium+ uptake by CAY10594 and halopemide was 
less than 29% on average at the highest concentration used (10 µM), and IC50 values for these 
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antagonists could not be reliably determined due to this low amount of inhibition (Fig. 4). 
Thus, the mode of action by which CAY10593 impairs P2X7 was studied further below. 
 
CAY10593 inhibits P2X7-induced pore formation in a non-competitive-like manner 
 
To determine whether CAY10593 inhibits P2X7-induced pore formation in a competitive or 
non-competitive manner, RPMI 8226 cells were pre-incubated in the presence of DMSO, or 2 
or 10 µM CAY10593, and then the ethidium+ uptake was measured in the presence of 
increasing concentrations of ATP. In the absence of CAY10593, ATP induced ethidium+ 
uptake in a concentration-dependent manner with maximal uptake occurring at 0.5 mM ATP 
and with an EC50 of 116 ± 31 µM (Fig. 5). In the presence of 2 µM CAY10593, the mean 
maximum ATP response was reduced by 17% and with a slight increase in the EC50 to 154 ± 
26 µM (Fig. 5). In the presence of 10 µM CAY10593, the mean maximum ATP response was 
reduced by 60% and with a larger increase in the EC50 to 256 ± 22 µM (Fig. 5).  
 
PLD signalling is not required for P2X7-induced pore formation 
 
Collectively, the above results show that the PLD1 specific antagonist CAY10593 can impair 
P2X7-induced pore formation. Therefore, to determine whether this effect is due to inhibition 
of PLD1 or direct inhibition of P2X7 itself, a series of experiments were performed. First, the 
presence of PLD1 and PLD2 in RPMI 8226 cells was examined by RT-PCR. The human skin 
epithelial carcinoma cell line, A431, which expresses both PLD isoforms [35], was used as a 
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positive control. RT-PCR revealed the presence of PLD1 in A431 cells but not in RPMI 8226 
cells, despite the presence of PLD2 in both cell lines (Fig. 6A). Choline-Cl medium has 
previously been shown to prevent P2X7-induced PLD stimulation [24,36]. Therefore RPMI 
8226 cells were suspended in either choline-Cl or NaCl medium and the ATP-induced 
ethidium+ uptake measured. ATP-induced ethidium+ uptake was potentiated in cells incubated 
in choline-Cl compared to NaCl medium (Fig. 6B). In the presence of a primary alcohol, PLD 
catalyses a transphosphatidylation reaction to form a phosphatidyl alcohol product, which 
does not serve as a substrate for PLD-mediated signal transduction [37]. Therefore, RPMI 
8226 cells were pre-incubated in the presence of the primary alcohol, 0.27 % (v/v) 1-butanol, 
or the secondary alcohol, 0.27% (v/v) 2-butanol as a negative control, and the ATP-induced 
ethidium+ uptake measured. ATP-induced ethidium+ uptake into cells treated with 1-butanol 
was also increased compared to cells treated with 2-butanol (Fig. 6C). In the absence of ATP, 
ethidium+ uptake into cells in choline-Cl or NaCl media in the presence of either alcohol was 
similar (results not shown). 
 
CAY10593 inhibits P2X7-induced channel activation and pore formation in P2X7-transfected 
HEK-293 cells 
 
The above results indicate that PLD signalling is not required for P2X7-induced pore 
formation and that CAY10593 directly impairs P2X7. Therefore, the effect of CAY10593 on 
P2X7 channel activity in human P2X7-transfected HEK-293 cells was assessed by 
electrophysiology. In the absence of 10 µM CAY10593, ATP induced an inward current 
typical of P2X7 (Fig. 7A). Removal of extracellular ATP, and subsequent 3-5 min incubation 
with 10 µM CAY10593 reduced the ATP-induced inward current to 29.5 ± 2.6 % of control 
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(Fig. 7A). To confirm that CAY10593 impairs P2X7 pore formation in these cells, P2X7-
transfected HEK-293 cells were pre-incubated with CAY10593 for 15 min at 37°C and ATP-
induced ethidium+ uptake was measured. CAY10593 impaired ATP-induced ethidium+ 
uptake into P2X7-transfected HEK-293 cells by 72% (Fig. 7B).  
 
CAY10593 inhibits P2X7-induced pore formation in human peripheral blood mononuclear 
cells 
 
To determine if CAY10593 inhibits P2X7-induced pore formation in primary cells, PBMCs 
from a human donor were pre-incubated in the presence of DMSO or 10 µM CAY10593 and 
ethidium+ uptake was measured in the absence or presence of ATP. CAY10593 inhibited 
ATP-induced ethidium+ uptake into B cells, T cells and monocytes by 66 ± 5%, 76 ± 3% and 
80 ± 4% respectively (Fig. 8). In the absence of ATP, CAY10593 did not significantly alter 
ethidium+ uptake compared to DMSO-treated cells (results not shown). Similar amounts of 
inhibition of ATP-induced ethidium+ uptake by CAY10593 were observed in B cells, T cells 




The current study demonstrates that the PLD1 antagonist, CAY10593 impairs human P2X7 
activation. Our preliminary investigations demonstrated that CAY10593 impaired ATP-
induced CD23 shedding. Moreover, CAY10593 impaired ATP-induced ethidium+ uptake into 
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RPMI 8226 cells in a concentration-dependent manner, and with an IC50 similar to that of the 
P2X7 antagonist, A-438079 as observed previously [34] and in this study. Unlike A-438079, 
however, which blocks P2X7 in a competitive manner [34], CAY10593 impaired P2X7 in a 
non-competitive-like manner. CAY10593 also impaired ATP-induced ethidium+ uptake into 
P2X7-transfected HEK-293 cells, and primary human B cells, T cells and monocytes. In 
contrast, CAY10593 failed to affect ATP-induced ethidium+ uptake into murine 
erythroleukemia cells (unpublished observations), which like RPMI 8226 cells also express 
endogenous P2X7 [12,38], indicating that CAY10593 does not act on murine P2X7. 
 
The current study also shows that CAY10593 impairs P2X7 activation independently of 
PLD1 stimulation. First, CAY10593 was far more effective at inhibiting P2X7-induced pore 
formation than halopemide, which both impair cellular PLD1 with similar efficacies [30]. 
Second, the IC50 value of CAY10593 for inhibition of P2X7-induced pore formation was two 
logs greater than that observed for the inhibition of phorbol 12-myristate-induced PLD1 
stimulation in the non-small-cell lung cancer cell line, Calu-1 [30] (2 µM vs. 11 nM, 
respectively). Third, PLD1 mRNA was absent in RPMI 8226 cells, indicating that these cells 
do not contain this PLD isoform. Fourth, the primary alcohol, 1-butanol, which prevents 
PLD-mediated signalling [37], did not impair P2X7-induced pore formation. In fact, 1-
butanol potentiated this process, similar to a previous study in which incubation with 1-
butanol increased P2X7-induced pore formation and cytolysis in murine macrophages 
compared to controls [39]. The authors of this previous study concluded that phosphatidic 
acid production, resulting from PLD stimulation, delays P2X7-induced pore formation and 
cytolysis. Thus, it is possible that PLD-induced phosphatidic acid production may also delay 
P2X7-induced pore formation in human cells. Fifth and similar to the effect of 1-butanol, 
P2X7-induced pore formation and CD23 shedding were not impaired in choline-Cl medium, 
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which prevents P2X7-induced PLD stimulation in murine macrophages [24] and human 
chronic lymphocytic leukemic lymphocytes [36]. Sixth, CAY10593 also impaired P2X7 
channel activity, which is not directly linked to the activation of intracellular signalling 
molecules [40]. Finally, it is unlikely that CAY10593 impairs P2X7 activity via a PLD2-
dependent mechanism despite the presence of PLD2 mRNA in RPMI 8226 cells; the PLD2 
inhibitor, CAY10594, was far less effective at impairing ATP-induced ethidium+ uptake and 
CD23 shedding compared to CAY10593. Combined this data highlights the importance of 
ensuring that antagonists used in intracellular signalling studies downstream of P2X7 
activation do not directly affect P2X7 itself. In this regard, CAY10593 has been used at 50 
µM to support a role for PLD in the generation of P2X7-induced microvesicles capable of 
activating macrophages [27]. However, our data suggests that CAY10593 may have also 
acted on P2X7 itself in this previous study. Conversely, our data in combination with that of 
Scott and colleagues [30] indicates that the use of CAY10593 at nanomolar concentrations 
will be of potential value in determining if PLD1 is involved in signalling pathways 
downstream of P2X7 activation. 
 
As noted above CAY10593 impaired P2X7-induced pore formation more efficaciously than 
CAY10594 or halopemide. Moreover, CAY10593 blocked P2X7-induced CD23 shedding to 
a greater extent than CAY10594 or halopemide. CAY10593 was originally synthesised via 
the modification of the 1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one analogue 
halopemide, but unlike halopemide, CAY10593 contains a chiral (S)-methyl group which 
prompts PLD1 preferring pharmacology [30]. CAY10594, which has a 1-phenyl-1,3,8-
triazaspiro[4,5]decan-4-one scaffold instead of a 1-(piperidin-4-yl)-1H-benzo[d]imidazol-
2(3H)-one scaffold, also lacks a chiral (S)-methyl group [30]. Therefore, this structural group 
may be of importance in the interaction of CAY10593 with P2X7. The scaffold or structural 
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groups of CAY10593 may provide useful leads in the development of new P2X7 antagonists. 
In this regard, the study of analogues of the P2X7 antagonist KN-62, which is also an 
inhibitor of Ca2+/calmodulin-dependent protein kinase II, has provided valuable insight into 
moieties which interact with P2X7 [41].  
 
Broad spectrum metalloprotease antagonists have implicated a role for metalloproteases in 
P2X7-induced CD23 shedding from chronic lymphocytic leukemic B-lymphocytes [16] and 
RPMI 8226 cells [17]. More recently, we have shown that P2X7-induced CD23 shedding is 
mediated by ADAM10 [29]. However, it is unknown if P2X7-induced CD23 shedding results 
from changes in intracellular cation concentrations, stimulation of signalling pathways 
downstream of P2X7 activation or by a direct physical interaction of P2X7 itself. The current 
study reports data exploring the first two of these potential mechanisms. In this study, we 
show that P2X7-induced CD23 shedding does not require changes in intracellular Na+, K+ or 
Ca2+ concentrations. Changes in intracellular cation concentrations are crucial for some 
P2X7-mediated downstream processes. For example, P2X7-induced IL-1β processing and 
release is dependent on K+ efflux from human monocytes [42-43], murine and human 
macrophages [44-46] and murine microglia [47]. Moreover, P2X7-induced secretion of IL-1β 
is dependent on the influx of extracellular Ca2+ and a sustained increase in intracellular Ca2+ 
in human monocytes [42,48], murine macrophages and P2X7-transfected HEK-293 cells 
[48]. Finally, P2X7-induced rapid phosphatidylserine exposure on murine thymocytes is 
dependent on Na+ influx [49]. In contrast to these studies, we found that neither K+ efflux, 
Na+ influx, Ca2+ influx nor an increase in intracellular Ca2+ is essential for P2X7-induced 
CD23 shedding from RPMI 8226 cells. Of note, choline-Cl and KCl medium potentiated 
ATP-induced CD23 shedding compared to NaCl medium, which is likely due to the omission 
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of extracellular Na+, a cation known to inhibit P2X7 activity [50-51], as well as the possible 
inhibition of phosphatidic acid production by choline as discussed above.  
The current study also reports that several signalling molecules downstream of P2X7 are 
unlikely to be involved in P2X7-induced CD23 shedding. However, it should be noted that 
the compounds used to target these enzymes were only used at a single concentration, and the 
efficacy of these compounds was not verified by relevant enzymatic assays. Thus the 
involvement of these signalling pathways in P2X7-induced CD23 shedding cannot be 
definitively excluded. Future studies, using large antagonist libraries and high throughput 
assays may prove a more useful approach to identify the potential signalling pathway 
mediating P2X7-induced CD23 shedding, rather than the candidate approach applied in this 
study. 
 
In conclusion, this study demonstrates the PLD1 antagonist, CAY10593, impairs human 
P2X7 independently of PLD1 stimulation. This study highlights the importance of ensuring 
that antagonists used in intracellular signalling studies downstream of P2X7 activation do not 
directly affect P2X7 itself. Moreover, this study suggests that CAY10593 may be of value in 
future studies of P2X7-induced PLD1 stimulation when used at nM concentrations, as well as 
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Fig. 1: P2X7 antagonists impair ATP-induced ethidium+ uptake into RPMI 8226 cells. RPMI 
8226 cells in NaCl medium were pre-incubated at 37°C for 15 min in the absence or presence 
of varying concentrations of antagonist (as indicated). Cells were then incubated with 25 µM 
ethidium+ in the absence or presence of 1 mM ATP at 37°C for 5 min. Incubations were 
stopped by addition of MgCl2 medium and centrifugation, and the mean fluorescence 
intensity (MFI) of ethidium+ uptake determined by flow cytometry. Results are the mean 
percent of ATP-induced ethidium+ uptake in the absence of antagonist ± SD (triplicate data 
from one experiment for each antagonist). 
 
Fig. 2: ATP-induced CD23 shedding from RPMI 8226 cells is not prevented by changes in 
intracellular cation concentrations. (A-D) Cells in NaCl medium, in (A) choline-Cl or (B) 
KCl medium, or in NaCl medium containing (C) 0.1 mM EGTA or (D) 50 µM BAPTA-AM 
were pre-incubated at 37°C for (A-C) 5 min or (D) 30 min. (A-D) Cells were then incubated 
in the absence or presence of 1 mM ATP at 37°C for 7 min. Incubations were stopped by 
addition of MgCl2 medium and centrifugation. Cells were labelled with PE-conjugated anti-
CD23 or isotype control mAb, and the mean fluorescence intensity (MFI) of cell-surface 
CD23 expression determined by flow cytometry. Results are the mean percent of ATP-
induced CD23 loss ± SD (triplicate data from one experiment for each comparison); * P < 
0.05 and ** P < 0.01 compared to NaCl medium. 
  
Fig. 3: PLD antagonists impair ATP-induced CD23 shedding and ethidium+ uptake in RPMI 
8226 cells. (A, B) Cells in NaCl medium were pre-incubated at 37°C for 15 min in the 
presence of DMSO, or 10 µM CAY10593, CAY10594 or halopemide. (A) Cells were then 
incubated in the absence or presence of 1 mM ATP at 37°C for 7 min. Incubations were 
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stopped by addition of MgCl2 medium and centrifugation. Cells were then labelled with PE-
conjugated anti-CD23 or isotype control mAb, and the mean fluorescence intensity (MFI) of 
cell-surface CD23 expression determined by flow cytometry. (B) Cells were then incubated 
with 25 µM ethidium+ in the absence or presence of 1 mM ATP at 37°C for 5 min. 
Incubations were stopped by addition of MgCl2 medium and centrifugation, and the mean 
fluorescence intensity (MFI) of ethidium+ uptake determined by flow cytometry. Results are 
the (A) mean percent of ATP-induced CD23 loss ± SD and (B) mean ATP-induced ethidium+ 
uptake ± SD (triplicate data from one experiment for each antagonist); * P < 0.05 and ** P < 
0.01 compared to DMSO.  
 
Fig. 4: CAY10593, CAY10594 and halopemide impair ATP-induced ethidium+ uptake into 
RPMI 8226 cells in a concentration-dependent manner. Cells in NaCl medium were pre-
incubated at 37°C for 15 min in the presence of DMSO or varying concentrations of 
antagonist (as indicated). Cells were then incubated with 25 µM ethidium+ in the absence or 
presence of 120 µM ATP at 37°C for 5 min. Incubations were stopped by addition of MgCl2 
medium and centrifugation, and the mean fluorescence intensity (MFI) of ethidium+ uptake 
determined by flow cytometry. Results are the mean percent of ATP-induced ethidium+ 
uptake in the absence of compound ± SD (triplicate data from one experiment for each 
antagonist).  
 
Fig. 5: CAY10593 impairs ATP-induced ethidium+ uptake into RPMI 8226 cells in a non-
competitive-like manner. RPMI 8226 cells in NaCl medium were pre-incubated at 37°C for 
15 min in the presence of DMSO, or 2 µM or 10 µM CAY10593. Cells were then incubated 
with 25 µM ethidium+ in the absence or presence of varying concentrations of ATP at 37°C 
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for 5 min. Incubations were stopped by addition of MgCl2 medium and centrifugation, and 
the mean fluorescence intensity (MFI) of ethidium+ uptake determined by flow cytometry. 
Results are the mean percent of maximum ATP (0.5 mM)-induced ethidium+ uptake ± SD 
(data from three independent experiments). 
 
Fig. 6: PLD1 is not required for ATP-induced ethidium+ uptake into RPMI 8226 cells. (A) 
RNA was isolated from A431 (positive control) and RPMI 8226 cells, and then analysed by 
RT-PCR using primers for PLD1 and PLD2. RNA substituted with H2O was used as a 
negative control. PCR products were visualised by agarose gel electrophoresis and ethidium 
bromide (representative result from three independent experiments is shown). (B, C) RPMI 
8226 cells were pre-incubated at 37°C for 5 min in (B) choline-Cl or NaCl medium, or (C) 
NaCl medium in the presence of 0.27% (v/v) 2-butanol (negative control) or 1-butanol. (B, 
C) Cells were then incubated with 25 µM ethidium+ in the absence or presence of 1 mM ATP 
at 37°C for 5 min. Incubations were stopped by addition of MgCl2 medium and 
centrifugation, and the mean fluorescence intensity (MFI) of ethidium+ uptake determined by 
flow cytometry. Results are the mean ATP-induced ethidium+ uptake ± SD (triplicate data 
from one experiment for each comparison); *P < 0.05 and ** P < 0.01 compared to 
corresponding control.  
 
Fig. 7:  CAY10593 impairs ATP-induced inward currents and pore formation in human 
P2X7-transfected HEK-293 cells. (A) Inward currents were elicited using 1 mM ATP in low 
divalent NaCl solution. ATP was added for 5 s (denoted by black bar) before and after 
treatment with 10 µM CAY10593 (3-5 minutes). ATP was added in the continued presence 
of CAY10593 (single representative trace of four to seven cells is shown). (B) P2X7-
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transfected HEK-293 cells in low divalent NaCl solution containing 25 µM ethidium+ were 
pre-incubated in the presence of DMSO or CAY10593 for 15 min at 37°C. ATP (1 mM) was 
injected after 40 s. Fluorescence was measured every 10 s using a plate reader (data from one 
experiment). 
 
Fig. 8: CAY10593 impairs ATP-induced ethidium+ uptake in primary human peripheral 
blood mononuclear cells (PBMCs). PBMCs in NaCl medium were pre-incubated for 15 min 
in the presence of DMSO or 10 µM CAY10593. Cells were then incubated with 25 µM 
ethidium+ in the absence or presence of 1 mM ATP at 37°C for 5 min. Incubations were 
stopped by addition of MgCl2 medium and centrifugation, and washed once with NaCl 
medium. Cells were then labelled with APC-conjugated anti-CD19. The mean fluorescence 
intensity (MFI) of ethidium+ uptake into (A) B cells (CD19+ lymphocytes), (B) T cells 
(CD19- lymphocytes) and (C) monocytes was determined by flow cytometry. Results are the 
mean ATP-induced ethidium+ uptake ± SD (triplicate data from one donor; similar amounts 
of inhibition were observed with triplicate data from a second donor, results not shown); **P 
< 0.01 compared to corresponding control. 








